Wen Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wen Liu has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Xiao Yan
Department of Pharmacy, The First Hospital Affiliated with Hunan Normal University (Hunan Provincial People’s Hospital), Changsha, 410005, People’s Republic of China
6 shared publicationsYu Jiang
Institute of Emergency Medicine, Department of Emergency, Hunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Hunan Provincial People’s Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, Hunan, People’s Republic of China
6 shared publicationsSha Li
Department of Pharmacy, Changsha Stomatological Hospital, Changsha 410005, China
4 shared publicationsFeiya Jiang
Department of Pharmacy, The First Affiliate Hospital of Hunan Normal University (Hunan Provincial People’s Hospital), Changsha 410005, China
3 shared publicationsJun Deng
Department of Pharmacy, Hunan Provincial People's Hospital (The First Affiliate Hospital of Hunan Normal University), Changsha 410000, China
3 shared publicationsTongtong Wang
Department of Pharmacy, Hunan Provincial People's Hospital (The First Affiliate Hospital of Hunan Normal University), Changsha 410000, China
3 shared publications
Latest Publications
- Open Access
- 1 June 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 4665-4688
Integration of Network Pharmacology, Transcriptomics, and Metabolomics Strategies to Uncover the Mechanism of Chaihuang Qingfu Pill in Treating Sepsis-Induced Liver Injury
Background: Sepsis is a critical condition triggered by infection and characterized by systemic inflammation and subsequent multiorgan failure. Chaihuang Qingfu Pill (CHQF), an in-hospital formulation developed by Hunan Provincial People’s Hospital, is derived from the traditional Chinese medicine compound Qingyi Decoction through optimized herbal compatibility. It possesses pharmacological activities including heat-clearing and purgation, choleretic and anti-jaundice effects, as well as Qi-regulation and mass-resolving properties. Clinically, CHQF is primarily used in the treatment of cholecystitis, pancreatitis, and hepatitis, and has shown potential therapeutic effects in alleviating sepsis-associated liver injury. However, the precise molecular mechanisms and omics-based investigations of CHQF in the context of sepsis remain poorly understood. The NF-κB signaling pathway serves as a central regulatory hub of the inflammatory response. Its activation leads to the excessive expression of pro-inflammatory mediators and cytokines, thereby exacerbating tissue damage and promoting the progression of inflammatory diseases. Consequently, targeting the NF-κB pathway may represent an effective therapeutic strategy for the treatment of sepsis. This study aims to systematically investigate the molecular basis of CHQF in the mitigation of sepsis-associated liver damage. Purpose: To explore the mechanism of CHQF for the treatment of sepsis-induced liver injury. Methods: A sepsis mouse model was established via cecal ligation and puncture (CLP). The pharmacological mechanisms of CHQF were explored using network pharmacology, transcriptomics, and metabolomics, which enabled the identification of potential therapeutic targets and pathways, as further validated by in vivo and in vitro experiments. Results: CHQF administration significantly improved the survival rates, reduced systemic inflammation, and restored liver function in CLP-induced sepsis mice, while also mitigating liver tissue injury. Network pharmacological analysis revealed paeoniflorin, quercetin, hyperforin, and wogonin as the core bioactive compounds of CHQF. Transcriptomic profiling identified key targets, including CD14, CXCL2, CCL2, BIRC5, and CXCL8, and demonstrated a significant downregulation of inflammatory cytokines such as TNF-α, IL-6, IL-1β, IL-17, CCL2, CCL3, CCL4, CXCL2, CXCL3, and CXCL5, alongside NF-κB signaling pathway inhibition. Metabolomic analysis indicated that CHQF treatment reduced the levels of sepsis-related metabolites, including lysophosphatidylcholine (22:6), lysophosphatidylcholine (18:1), 1-LGPC, and C17-sphinganine. Conclusion: Collectively, these findings suggest that CHQF alleviates sepsis-induced liver injury by modulating the inflammatory response via NF-κB signaling pathway inhibition. This study provides novel insights into the complex molecular mechanisms underlying the therapeutic effects of CHQF in sepsis and enhances the understanding of the pharmacological actions of traditional Chinese medicine in managing sepsis.
- 1 June 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 4665-4688
Open AccessIntegration of Network Pharmacology, Transcriptomics, and Metabolomics Strategies to Uncover the Mechanism of Chaihuang Qingfu Pill in Treating Sepsis-Induced Liver Injury
Background: Sepsis is a critical condition triggered by infection and characterized by systemic inflammation and subsequent multiorgan failure. Chaihuang Qingfu Pill (CHQF), an in-hospital formulation developed by Hunan Provincial People’s Hospital, is derived from the traditional Chinese medicine compound Qingyi Decoction through optimized herbal compatibility. It possesses pharmacological activities including heat-clearing and purgation, choleretic and anti-jaundice effects, as well as Qi-regulation and mass-resolving properties. Clinically, CHQF is primarily used in the treatment of cholecystitis, pancreatitis, and hepatitis, and has shown potential therapeutic effects in alleviating sepsis-associated liver injury. However, the precise molecular mechanisms and omics-based investigations of CHQF in the context of sepsis remain poorly understood. The NF-κB signaling pathway serves as a central regulatory hub of the inflammatory response. Its activation leads to the excessive expression of pro-inflammatory mediators and cytokines, thereby exacerbating tissue damage and promoting the progression of inflammatory diseases. Consequently, targeting the NF-κB pathway may represent an effective therapeutic strategy for the treatment of sepsis. This study aims to systematically investigate the molecular basis of CHQF in the mitigation of sepsis-associated liver damage. Purpose: To explore the mechanism of CHQF for the treatment of sepsis-induced liver injury. Methods: A sepsis mouse model was established via cecal ligation and puncture (CLP). The pharmacological mechanisms of CHQF were explored using network pharmacology, transcriptomics, and metabolomics, which enabled the identification of potential therapeutic targets and pathways, as further validated by in vivo and in vitro experiments. Results: CHQF administration significantly improved the survival rates, reduced systemic inflammation, and restored liver function in CLP-induced sepsis mice, while also mitigating liver tissue injury. Network pharmacological analysis revealed paeoniflorin, quercetin, hyperforin, and wogonin as the core bioactive compounds of CHQF. Transcriptomic profiling identified key targets, including CD14, CXCL2, CCL2, BIRC5, and CXCL8, and demonstrated a significant downregulation of inflammatory cytokines such as TNF-α, IL-6, IL-1β, IL-17, CCL2, CCL3, CCL4, CXCL2, CXCL3, and CXCL5, alongside NF-κB signaling pathway inhibition. Metabolomic analysis indicated that CHQF treatment reduced the levels of sepsis-related metabolites, including lysophosphatidylcholine (22:6), lysophosphatidylcholine (18:1), 1-LGPC, and C17-sphinganine. Conclusion: Collectively, these findings suggest that CHQF alleviates sepsis-induced liver injury by modulating the inflammatory response via NF-κB signaling pathway inhibition. This study provides novel insights into the complex molecular mechanisms underlying the therapeutic effects of CHQF in sepsis and enhances the understanding of the pharmacological actions of traditional Chinese medicine in managing sepsis.
- 25 July 2023
- Published by Elsevier in Microbes and Infection
- Vol. 25 (8) , 105189
A retrospective analysis of Q fever osteomyelitis in children, with recommendations
- 25 July 2023
- Published by Elsevier in Microbes and Infection
- Vol. 25 (8) , 105189
A retrospective analysis of Q fever osteomyelitis in children, with recommendations
- 27 January 2023
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 14 (4) , 2112-2127
Analysis of the mechanism of action of quercetin in the treatment of hyperlipidemia based on metabolomics and intestinal flora
Hyperlipidemia (HLP) is one of the main factors leading to cardiovascular diseases. Quercetin (QUE) is a naturally occurring polyhydroxy flavonoid compound that has a wide range of pharmacological effects. However, the potential mechanism for treating HLP remains unclear. Thus, the study aimed to investigate the role of QUE in HLP development and its underlying mechanisms in HLP rats based on the analysis of gut microbiota and plasma metabolomics. Following the establishment of an HLP model in rats, QUE was orally administered. Plasma samples and fecal samples were collected from HLP rats for microbiome 16S rDNA sequencing and metabolic UPLC-Q-Exactive-MS analysis. The results suggested that QUE could regulate dyslipidemia and inhibit the levels of TC, TG, and LDL-c. Additionally, histopathological findings revealed that QUE could reduce lipid deposition, ameliorate hepatic injury and steatosis in HFD-induced rats, and have a protective effect on the liver. The analysis and identification of plasma metabolomics showed that the intervention effect of QUE on HLP rats was related to 60 differential metabolites and signal pathways such as lactosamine, 11b-hydroxyprogesterone, arachidonic acid, glycerophospholipid, sphingolipid, glycerolipid, and linoleic acid metabolism. Combined with fecal microbiological analysis, it was found that QUE could significantly change the composition of intestinal flora in HLP rats, increase beneficial bacteria, and reduce the composition of harmful bacteria, attenuating the Firmicutes/Bacteroidetes ratio. The results of correlation analysis showed that the relative abundance level of Firmicutes, Deironobacterium, Fusobacterium, Bacteroides, and Escherichia coli was closely related to the change of differential metabolites. In summary, combined with metabolomics and gut microbiota studies, it is found that QUE can reduce lipid levels and improve liver function. The potential mechanism may be the regulation of metabolism and intestinal flora that play a role in reducing lipid levels, to achieve the purpose of treatment of HLP.
- 27 January 2023
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 14 (4) , 2112-2127
Analysis of the mechanism of action of quercetin in the treatment of hyperlipidemia based on metabolomics and intestinal flora
Hyperlipidemia (HLP) is one of the main factors leading to cardiovascular diseases. Quercetin (QUE) is a naturally occurring polyhydroxy flavonoid compound that has a wide range of pharmacological effects. However, the potential mechanism for treating HLP remains unclear. Thus, the study aimed to investigate the role of QUE in HLP development and its underlying mechanisms in HLP rats based on the analysis of gut microbiota and plasma metabolomics. Following the establishment of an HLP model in rats, QUE was orally administered. Plasma samples and fecal samples were collected from HLP rats for microbiome 16S rDNA sequencing and metabolic UPLC-Q-Exactive-MS analysis. The results suggested that QUE could regulate dyslipidemia and inhibit the levels of TC, TG, and LDL-c. Additionally, histopathological findings revealed that QUE could reduce lipid deposition, ameliorate hepatic injury and steatosis in HFD-induced rats, and have a protective effect on the liver. The analysis and identification of plasma metabolomics showed that the intervention effect of QUE on HLP rats was related to 60 differential metabolites and signal pathways such as lactosamine, 11b-hydroxyprogesterone, arachidonic acid, glycerophospholipid, sphingolipid, glycerolipid, and linoleic acid metabolism. Combined with fecal microbiological analysis, it was found that QUE could significantly change the composition of intestinal flora in HLP rats, increase beneficial bacteria, and reduce the composition of harmful bacteria, attenuating the Firmicutes/Bacteroidetes ratio. The results of correlation analysis showed that the relative abundance level of Firmicutes, Deironobacterium, Fusobacterium, Bacteroides, and Escherichia coli was closely related to the change of differential metabolites. In summary, combined with metabolomics and gut microbiota studies, it is found that QUE can reduce lipid levels and improve liver function. The potential mechanism may be the regulation of metabolism and intestinal flora that play a role in reducing lipid levels, to achieve the purpose of treatment of HLP.
- Open Access
- 1 December 2021
- Published by China Science Publishing & Media Ltd. in Journal of Zhejiang University (Medical Sciences)
- Vol. 50 (6) , 722-729
Risk probability model for residual metastatic lymph node in patients with papillary thyroid microcarcinoma undergoing cervical central lymph node dissection
通过大样本甲状腺微小乳头状癌(PTMC)队列建立概率模型,量化颈部中央淋巴结(简称中央淋巴结)清扫术后残余转移性淋巴结风险。 回顾性分析2007—2020年昆明医科大学第一附属医院甲状腺疾病诊治中心诊断为PTMC、由高手术量医生执行甲状腺切除+中央淋巴结清扫且至少检测1枚淋巴结的病例,进一步描述阳性淋巴结的分布特征并建立评价隐匿性转移性淋巴结风险的数学模型。使用β-二项分布估计隐匿性转移性中央淋巴结的概率作为淋巴结清扫(检测)数的函数。 概率模型共纳入5399例连续病例,观察到转移性中央淋巴结1664例(30.8%)。经过模型校正,真实淋巴结转移率由30.8%升高至38.9%。在清扫(检测)1枚淋巴结时,中央淋巴结假阴性的概率为31.3%,而当清扫(检测)7枚和12枚淋巴结时,假阴性的概率分别降低至10.0%和4.9%。合并桥本甲状腺炎病例的概率模型敏感性分析与主分析显示基本一致的稳健结果。 本研究量化了PTMC患者中央淋巴结清扫术后的隐匿性残余转移性淋巴结风险,可以作为评估术后复发/残余风险的补充指标,也为通过回顾性数据资料评估残余转移性淋巴结对肿瘤患者预后的影响提供新的方法。
- 1 December 2021
- Published by China Science Publishing & Media Ltd. in Journal of Zhejiang University (Medical Sciences)
- Vol. 50 (6) , 722-729
Open AccessRisk probability model for residual metastatic lymph node in patients with papillary thyroid microcarcinoma undergoing cervical central lymph node dissection
通过大样本甲状腺微小乳头状癌(PTMC)队列建立概率模型,量化颈部中央淋巴结(简称中央淋巴结)清扫术后残余转移性淋巴结风险。 回顾性分析2007—2020年昆明医科大学第一附属医院甲状腺疾病诊治中心诊断为PTMC、由高手术量医生执行甲状腺切除+中央淋巴结清扫且至少检测1枚淋巴结的病例,进一步描述阳性淋巴结的分布特征并建立评价隐匿性转移性淋巴结风险的数学模型。使用β-二项分布估计隐匿性转移性中央淋巴结的概率作为淋巴结清扫(检测)数的函数。 概率模型共纳入5399例连续病例,观察到转移性中央淋巴结1664例(30.8%)。经过模型校正,真实淋巴结转移率由30.8%升高至38.9%。在清扫(检测)1枚淋巴结时,中央淋巴结假阴性的概率为31.3%,而当清扫(检测)7枚和12枚淋巴结时,假阴性的概率分别降低至10.0%和4.9%。合并桥本甲状腺炎病例的概率模型敏感性分析与主分析显示基本一致的稳健结果。 本研究量化了PTMC患者中央淋巴结清扫术后的隐匿性残余转移性淋巴结风险,可以作为评估术后复发/残余风险的补充指标,也为通过回顾性数据资料评估残余转移性淋巴结对肿瘤患者预后的影响提供新的方法。
- RetractedOpen Access
- 27 August 2021
- Published by Wiley in Bioinorganic Chemistry and Applications
- Vol. 2021, 1-6
Porous Lactose as a Novel Ingredient Carrier for the Improvement of Quercetin Solubility In Vitro
In this work, quercetin was loaded in the highly-porous lactose via the adsorption of quercetin molecules in ethanol. The method aims to improve the quercetin solubility and the loading capacity of lactose. The method relates to the synthesis of the highly-porous lactose with a particle size of 35μm, a mean pore width of 30nm, a BET surface area of 35.0561±0.4613m2/g, and a BJH pore volume of 0.075346cc/g. After the quercetin loading in ethanol, BET surface area and BJH pore volume of porous lactose were reduced to 28.8735±0.3526m2/g and 0.073315cc/g, respectively. The reduction rate was based on the quercetin loading efficiency of highly-porous lactose. DSC analysis and XRD analysis suggest that the sediments of quercetin in the nanopores of porous lactose are crystalline. FTIR spectroscopy results suggest that there is no significant interaction between quercetin and lactose. The highly-porous lactose had a higher loading efficiency of 20.3 (w/w) compared to the α-lactose (with 5.2 w/w). The release rates of quercetin from the highly-porous lactose tablets were faster compared to the conventional α-lactose carrier.
- 27 August 2021
- Published by Wiley in Bioinorganic Chemistry and Applications
- Vol. 2021, 1-6
RetractedOpen AccessPorous Lactose as a Novel Ingredient Carrier for the Improvement of Quercetin Solubility In Vitro
In this work, quercetin was loaded in the highly-porous lactose via the adsorption of quercetin molecules in ethanol. The method aims to improve the quercetin solubility and the loading capacity of lactose. The method relates to the synthesis of the highly-porous lactose with a particle size of 35μm, a mean pore width of 30nm, a BET surface area of 35.0561±0.4613m2/g, and a BJH pore volume of 0.075346cc/g. After the quercetin loading in ethanol, BET surface area and BJH pore volume of porous lactose were reduced to 28.8735±0.3526m2/g and 0.073315cc/g, respectively. The reduction rate was based on the quercetin loading efficiency of highly-porous lactose. DSC analysis and XRD analysis suggest that the sediments of quercetin in the nanopores of porous lactose are crystalline. FTIR spectroscopy results suggest that there is no significant interaction between quercetin and lactose. The highly-porous lactose had a higher loading efficiency of 20.3 (w/w) compared to the α-lactose (with 5.2 w/w). The release rates of quercetin from the highly-porous lactose tablets were faster compared to the conventional α-lactose carrier.
- Open Access
- 20 July 2021
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 6 (30) , 19717-19730
Mechanistic Investigation of Xuebijing for Treatment of Paraquat-Induced Pulmonary Fibrosis by Metabolomics and Network Pharmacology
- 20 July 2021
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 6 (30) , 19717-19730
Open AccessMechanistic Investigation of Xuebijing for Treatment of Paraquat-Induced Pulmonary Fibrosis by Metabolomics and Network Pharmacology
- Open Access
- 26 March 2021
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 23 (6) , 1-10
Fluorofenidone attenuates paraquat‑induced pulmonary fibrosis by regulating the PI3K/Akt/mTOR signaling pathway and autophagy
Paraquat (PQ) is a widely used herbicide that is severely toxic to humans and animals. Pulmonary fibrosis is a disorder that can result from PQ poisoning. Fluorofenidone (AKF‑PD) is a novel small molecule pyridone drug with a widespread and clear anti‑organ fibrosis effect; however, its mechanism of action on PQ poisoning‑induced pulmonary fibrosis is not clear. The purpose of the present study was to investigate the protective effect and underlying mechanism of AKF‑PD on PQ poisoning‑induced pulmonary fibrosis. Human alveolar epithelial cells (HPAEpiC) and Sprague‑Dawley rats were treated with AKF‑PD in the presence or absence of PQ. Hematoxylin‑eosin and Masson staining were used to observe the morphological changes in lung tissue. Cell Counting Kit‑8 and lactate dehydrogenase assays were used to evaluate the viability of HPAEpiC cells. ELISA was used to detect inflammatory factors and the collagen content. Finally, the effects of AKF‑PD on pulmonary fibrosis, as well as the underlying mechanisms, were evaluated via western blotting, reverse transcription‑quantitative PCR and immunofluorescence analysis. AKF‑PD effectively alleviated PQ‑induced pulmonary fibrosis and reduced the expression of oxidative stress and inflammatory factors. Moreover, AKF‑PD treatment effectively inhibited the PI3K/Akt/mTOR signaling pathway and upregulated autophagy. Overall, these findings suggested that AKF‑PD can alleviate PQ‑induced inflammation and pulmonary fibrosis by inhibiting the PI3K/Akt/mTOR signaling pathway and by upregulating autophagy.
- 26 March 2021
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 23 (6) , 1-10
Open AccessFluorofenidone attenuates paraquat‑induced pulmonary fibrosis by regulating the PI3K/Akt/mTOR signaling pathway and autophagy
Paraquat (PQ) is a widely used herbicide that is severely toxic to humans and animals. Pulmonary fibrosis is a disorder that can result from PQ poisoning. Fluorofenidone (AKF‑PD) is a novel small molecule pyridone drug with a widespread and clear anti‑organ fibrosis effect; however, its mechanism of action on PQ poisoning‑induced pulmonary fibrosis is not clear. The purpose of the present study was to investigate the protective effect and underlying mechanism of AKF‑PD on PQ poisoning‑induced pulmonary fibrosis. Human alveolar epithelial cells (HPAEpiC) and Sprague‑Dawley rats were treated with AKF‑PD in the presence or absence of PQ. Hematoxylin‑eosin and Masson staining were used to observe the morphological changes in lung tissue. Cell Counting Kit‑8 and lactate dehydrogenase assays were used to evaluate the viability of HPAEpiC cells. ELISA was used to detect inflammatory factors and the collagen content. Finally, the effects of AKF‑PD on pulmonary fibrosis, as well as the underlying mechanisms, were evaluated via western blotting, reverse transcription‑quantitative PCR and immunofluorescence analysis. AKF‑PD effectively alleviated PQ‑induced pulmonary fibrosis and reduced the expression of oxidative stress and inflammatory factors. Moreover, AKF‑PD treatment effectively inhibited the PI3K/Akt/mTOR signaling pathway and upregulated autophagy. Overall, these findings suggested that AKF‑PD can alleviate PQ‑induced inflammation and pulmonary fibrosis by inhibiting the PI3K/Akt/mTOR signaling pathway and by upregulating autophagy.
- 5 February 2021
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 27, e930166-e930166-14
Effect of Fluorofenidone Against Paraquat-Induced Pulmonary Fibrosis Based on Metabolomics and Network Pharmacology
Effect of Fluorofenidone Against Paraquat-Induced Pulmonary Fibrosis Based on Metabolomics and Network Pharmacology - Article abstract #930166
- 5 February 2021
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 27, e930166-e930166-14
Effect of Fluorofenidone Against Paraquat-Induced Pulmonary Fibrosis Based on Metabolomics and Network Pharmacology
Effect of Fluorofenidone Against Paraquat-Induced Pulmonary Fibrosis Based on Metabolomics and Network Pharmacology - Article abstract #930166
- Open Access
- 13 August 2020
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 12 (37) , 4562-4571
Metabolic profiling of rats poisoned with paraquat and treated with Xuebijing using a UPLC-QTOF-MS/MS metabolomics approach
In this study, we used an UPLC-QTOF-MS/MS metabolomics approach combined with pattern recognition, cluster analysis, and metabolic pathway analyses to investigate changes in metabolite levels in SD rats poisoned with PQ and subsequently treated with XBJ or left untreated.
- 13 August 2020
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 12 (37) , 4562-4571
Open AccessMetabolic profiling of rats poisoned with paraquat and treated with Xuebijing using a UPLC-QTOF-MS/MS metabolomics approach
In this study, we used an UPLC-QTOF-MS/MS metabolomics approach combined with pattern recognition, cluster analysis, and metabolic pathway analyses to investigate changes in metabolite levels in SD rats poisoned with PQ and subsequently treated with XBJ or left untreated.